SCHEMBL13330735

SCHEMBL13330735

c1ccc(-c2c(-c3ccccc3)c(-c3ccccc3)c(-c3ccc4c(c3)c3cc(-c5c(-c6ccccc6)c(-c6ccccc6)c(-c6ccccc6)c(-c6ccccc6)c5-c5ccccc5)ccc3c3nccnc43)c(-c3ccccc3)c2-c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.40
JAK2 O60674 2/20 0.40
PIK3CA P42336 1/20 0.36
MAP4K4 O95819 2/20 0.35
TOP1 P11387 2/20 0.35
DCLK1 O15075 1/20 0.35
PRKD3 O94806 1/20 0.35
CHEK2 O96017 1/20 0.35
CSF1R P07333 1/20 0.35
FER P16591 1/20 0.35
CDK2 P24941 1/20 0.35
MARK3 P27448 1/20 0.35
FLT4 P35916 1/20 0.35
FLT3 P36888 1/20 0.35
MAPK9 P45984 1/20 0.35
CSNK1D P48730 1/20 0.35
CLK2 P49760 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CSNK1G2 P78368 1/20 0.35
MAP4K2 Q12851 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11932672 0.88 MKNK1 (0.46) MKNK1JAK2PIK3CAMAP4K4CLK2
SCHEMBL12722831 0.85 MKNK1 (0.44) MKNK1JAK2PIK3CAMAP4K4CLK2
SCHEMBL16543288 0.81 MEN1 (0.37) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL16543278 0.81 MEN1 (0.37) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL16543266 0.81 MEN1 (0.37) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL16543272 0.81 MEN1 (0.37) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL14803465 0.81 MEN1 (0.37) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL14803614 0.80 ALDH1A1 (0.39) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL14803837 0.79 MEN1 (0.36) MKNK1JAK2PIK3CAMAP4K4ALK
SCHEMBL16543265 0.79 MEN1 (0.36) MKNK1JAK2PIK3CAMAP4K4ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353065-B2 Heterocyclic bridged biphenyls BASF SE (DE) 2016-05-31 US disclosed
US-9353065-B2 Heterocyclic bridged biphenyls BASF SE (DE) 2016-05-31 US disclosed
EP-2125752-B1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (DE) 2015-08-12 EP disclosed
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS UDC IRELAND LIMITED (IE) 2010-05-06 US disclosed
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS UDC IRELAND LIMITED (IE) 2010-05-06 US disclosed
WO-2008119666-A1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS OCIAD1, SBDS, OCIAD2 MKNK1 4076/4885JAK2 4502/4885PIK3CA 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.